1. Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26(7):1607-1619. doi: 10.1185/03007995.2010.483675
  2. ZTLIDO® (lidocaine topical system) 1.8%. Prescribing information. SCILEX Pharmaceuticals; April 2021.
  3. Johnson P, Becker L, Halpern R, Sweeney M. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013;33(1):35- 44. doi: 10.1007/s40261-012-0030-4
  4. Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104-114. doi: 10.1177/2049463720912496
  5. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25(1):81-104. doi: 10.1016/s0149-2918(03)90011-7
  6. Rice ASC, Maton S; Postherpetic Neuralgia Study Group Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215-224. doi: 10.1016/S0304-3959(01)00407-9
  7. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938.
    doi: 10.1002/14651858. CD007938.pub4
  8. Neurontin (gabapentin). Prescribing information. Pfizer; 2021.
  9. Lyrica (pregabalin) capsules, CV. Prescribing information. Parke-Davis; 2020.
  10. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837-(18)42. doi: 10.1001/jama.280.21.1837
  11. Geha PY, Baliki MN, Chialvo DR, Harden RN, Paice JA, Apkarian AV. Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain. 2007;128(1-2):88-100. doi: 10.1016/j.pain.2006.09.014
  12. SCILEX Pharmaceuticals Inc. Data on file.
  13. Binder A, Rogers P, Hans G, Baron R. Impact of topical 5% lidocaine-medicated plasters on sleep and quality of life in patients with postherpetic neuralgia. Pain Manag. 2016;6(3):229-239. doi:10.2217/pmt-2015-0010
  14. Rampakakis E, Ste-Marie PA, Sampalis JS, et al. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015;1(1):e000146. doi:10.1136/rmdopen-2015-000146
  15. Gudin J, Webster LR, Greuber E, Vought K, Patel K, Kuritzky L. Open-label adhesion performance studies of a new lidocaine topical system 1.8% versus lidocaine patches 5% and lidocaine medicated plaster 5% in healthy subjects. J Pain Res. 2021;14:513-526. doi: 10.2147/JPR.S287153
  16. Lidoderm® (Lidocaine Patch 5%). Prescribing information. Endo Pharmaceuticals, Inc.; November 2018.
  17. Webster L, Mallick-Searle T, Adler JA, Greuber E, Patel K, Vought K. ZTlido® (lidocaine topical system) 1.8% has superior adhesion compared to generic Mylan lidocaine patch 5%. Poster presented at: PAINWeek; September 3-7, 2019; Las Vegas, NV.
  18. Fudin J, Wegrzyn EL, Greuber E, Vought K, Patel K, Nalamachu S. A randomized, crossover, pharmacokinetic and adhesion performance study of a lidocaine topical system 1.8% during physical activity and heat treatment in healthy subjects. J Pain Res. 2020;13:1359-1367. doi: 10.2147/JPR.S238268
  19. Vought K, Greuber E, Patel K, Argoff C, Lissin D. A randomized, crossover, adhesion performance and pharmacokinetic study of a lidocaine topical system under conditions of water exposure in healthy subjects. J Pain Res. 2021;14:2459-2467. doi:10.2147/JPR.S323789